Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Department of Oncology, Shanghai Medical College of Fudan University, Shanghai, China.
Gut. 2023 Nov 24;72(12):2329-2343. doi: 10.1136/gutjnl-2022-329349.
Pancreatic ductal adenocarcinoma (PDAC) is among the most immunosuppressive tumour types. The tumour immune microenvironment (TIME) is largely driven by interactions between immune cells and heterogeneous tumour cells. Here, we aimed to investigate the mechanism of tumour cells in TIME formation and provide potential combination treatment strategies for PDAC patients based on genotypic heterogeneity.
Highly multiplexed imaging mass cytometry, RNA sequencing, mass cytometry by time of flight and multiplex immunofluorescence staining were performed to identify the pro-oncogenic proteins associated with low immune activation in PDAC. An in vitro coculture system, an orthotopic PDAC allograft tumour model, flow cytometry and immunohistochemistry were used to explore the biological functions of cysteine-rich intestinal protein 1 (CRIP1) in tumour progression and TIME formation. RNA sequencing, mass spectrometry and chromatin immunoprecipitation were subsequently conducted to investigate the underlying mechanisms of CRIP1.
Our results showed that CRIP1 was frequently upregulated in PDAC tissues with low immune activation. Elevated CRIP1 expression induced high levels of myeloid-derived suppressor cell (MDSC) infiltration and fostered an immunosuppressive tumour microenvironment. Mechanistically, we primarily showed that CRIP1 bound to nuclear factor kappa-B (NF-κB)/p65 and facilitated its nuclear translocation in an importin-dependent manner, leading to the transcriptional activation of CXCL1/5. PDAC-derived CXCL1/5 facilitated the chemotactic migration of MDSCs to drive immunosuppression. SX-682, an inhibitor of CXCR1/2, blocked tumour MDSC recruitment and enhanced T-cell activation. The combination of anti-PD-L1 therapy with SX-682 elicited increased CD8+T cell infiltration and potent antitumor activity in tumour-bearing mice with high CRIP1 expression.
The CRIP1/NF-κB/CXCL axis is critical for triggering immune evasion and TIME formation in PDAC. Blockade of this signalling pathway prevents MDSC trafficking and thereby sensitises PDAC to immunotherapy.
胰腺导管腺癌(PDAC)是最具免疫抑制性的肿瘤类型之一。肿瘤免疫微环境(TIME)主要由免疫细胞与异质性肿瘤细胞之间的相互作用驱动。在这里,我们旨在研究肿瘤细胞在 TIME 形成中的机制,并基于基因型异质性为 PDAC 患者提供潜在的联合治疗策略。
采用高多重化成像质谱流式细胞术、RNA 测序、飞行时间质谱流式细胞术和多重免疫荧光染色,鉴定与 PDAC 中低免疫激活相关的原癌蛋白。采用体外共培养系统、原位 PDAC 同种异体移植肿瘤模型、流式细胞术和免疫组织化学,探讨富含半胱氨酸的肠蛋白 1(CRIP1)在肿瘤进展和 TIME 形成中的生物学功能。随后进行 RNA 测序、质谱和染色质免疫沉淀,以研究 CRIP1 的潜在机制。
我们的结果表明,CRIP1 在具有低免疫激活的 PDAC 组织中经常上调。CRIP1 表达水平的升高诱导了大量髓源抑制细胞(MDSC)浸润,并促进了免疫抑制性肿瘤微环境的形成。从机制上讲,我们主要表明 CRIP1 与核因子 kappa-B(NF-κB)/p65 结合,并以依赖导入蛋白的方式促进其核易位,导致 CXCL1/5 的转录激活。PDAC 衍生的 CXCL1/5 促进 MDSC 的趋化迁移,从而驱动免疫抑制。CXCR1/2 的抑制剂 SX-682 阻断肿瘤 MDSC 募集并增强 T 细胞激活。在高 CRIP1 表达的荷瘤小鼠中,抗 PD-L1 治疗与 SX-682 联合使用可增加 CD8+T 细胞浸润并增强抗肿瘤活性。
CRIP1/NF-κB/CXCL 轴对于触发 PDAC 中的免疫逃逸和 TIME 形成至关重要。阻断该信号通路可防止 MDSC 迁移,从而使 PDAC 对免疫治疗敏感。